$ORMP

NeoGenomics (NEO), BlossomHill Therapeutics (BLSM), Revolution Medicines (RVMD), Oramed Pharmaceuticals (ORMP), and Candel Therapeutics (CADL) reached 52-week highs on August 27, 2026. NEO reported Q2 revenue growth of 11% and a profit turnaround. BLSM began trading on Nasdaq and received FDA Fast Track designation. RVMD's lead drug, Rasonque, was FDA-approved. ORMP's net income increased significantly. CADL reported a higher net loss but plans a BLA filing for its lead drug.

Hexter Joshua (COO & CBO) sold 137,000 shares of ORAMED PHARMACEUTICALS INC. (ORMP) at $4.46 ($0.61M total) on 2026-07-01 under a Rule 10b5-1 trading plan.

Oramed Pharmaceuticals said in a shareholder letter it will be added to the Russell 2000 and Russell 3000 indexes effective June 29, 2026. The company reported its Alpha Tau (DRTS) position is up about $128 million to ~$167 million (incl. warrants), and that its Scilex (SCLX) $99.5 million loan has been substantially repaid, with ~$43 million expected by Oct. 2026. Oramed also cited total cash and assets of about $270 million as of March 31, 2026.

Oramed Pharmaceuticals (NASDAQ: ORMP) said it will be added to the Russell 2000 and Russell 3000 indexes after the 2026 semi-annual reconstitution, effective at the market open June 29, 2026. FTSE Russell’s preliminary additions were posted May 22, with final changes after June 26 close. Russell membership can also trigger inclusion in Russell 1000/2000 and style indexes, according to FTSE Russell.

Oramed Pharmaceuticals Inc.'s Chief Scientific Officer, Miriam Kidron, reported a tax-related disposition of 435,084 common shares to cover tax withholding obligations from vested Restricted Stock Units. The shares were valued at $3.31 each. Following this transaction, Kidron directly holds 1,133,138 shares of Oramed common stock.

Oramed Pharmaceuticals Inc. announced that Scilex Holding Company has completed the repurchase of all remaining warrants previously held by Oramed to purchase shares of Scilex common stock, totaling $28.5 million for 6,500,000 shares. This transaction involved two tranches, with Scilex paying $14 million on December 30 for 3,370,000 warrants and an earlier $13 million on September 30 for 3,130,000 warrants, plus $1.5 million in option fees. These repurchases were part of an option agreement disclosed in July and follows other strategic adjustments for Oramed, including the termination of a joint venture and plans to independently advance its oral insulin program.

Oramed Pharmaceuticals finalized a warrant repurchase with Scilex totaling $28.5 million on December 30, 2025. This involved Scilex repurchasing 3,370,000 shares for $14 million and an initial tranche of 3,130,000 shares for $13 million, with each tranche including a $750,000 option fee. The details of this transaction were filed with the SEC.

Oramed Pharmaceuticals Inc. (ORMP) announced that Leonard Sank, a long-serving director, will resign from its board effective January 1, 2026, after 18 years. The company stated this departure is not due to disagreements, indicating a smooth governance transition despite the loss of a long-tenured board member. TipRanks' AI Analyst, Spark, rates ORMP as Neutral, citing a strong balance sheet but weak operations and continued cash burn.

Oramed Pharmaceuticals Inc. completed the sale of warrants to Scilex Holding Company for a total of $28.5 million, significantly boosting its liquidity. This transaction involved Scilex repurchasing 6.5 million shares of Scilex common stock held by Oramed in two tranches. The financial flexibility gained is expected to support Oramed's biopharmaceutical operations.

Oramed Pharmaceuticals Inc. announced the resignation of director Leonard Sank, effective January 1, 2026. Sank's departure after 18 years was not due to disagreements with the company's operations. This announcement follows Oramed's recent financial transactions, including warrant repurchases by Scilex Holding Company and a share repurchase from Hefei Tianhui Biotech Co., Ltd., alongside the termination of their joint venture to advance an oral insulin program independently.